WO2002050301A3 - Gene expression profiles associated with osteoblast differentiation - Google Patents

Gene expression profiles associated with osteoblast differentiation Download PDF

Info

Publication number
WO2002050301A3
WO2002050301A3 PCT/US2001/048276 US0148276W WO0250301A3 WO 2002050301 A3 WO2002050301 A3 WO 2002050301A3 US 0148276 W US0148276 W US 0148276W WO 0250301 A3 WO0250301 A3 WO 0250301A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene expression
present
expression profiles
profiles associated
osteoblast differentiation
Prior art date
Application number
PCT/US2001/048276
Other languages
French (fr)
Other versions
WO2002050301A2 (en
Inventor
Darren Ji
Douglas W Axelrod
Jonathan S Cook
Neelam Jaiswal
Richard Einstein
Adam Houghton
Lawrence Mertz
Original Assignee
Gene Logic Inc
Procter & Gamble
Darren Ji
Douglas W Axelrod
Jonathan S Cook
Neelam Jaiswal
Richard Einstein
Adam Houghton
Lawrence Mertz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gene Logic Inc, Procter & Gamble, Darren Ji, Douglas W Axelrod, Jonathan S Cook, Neelam Jaiswal, Richard Einstein, Adam Houghton, Lawrence Mertz filed Critical Gene Logic Inc
Priority to CA002433436A priority Critical patent/CA2433436A1/en
Priority to AU2002230820A priority patent/AU2002230820A1/en
Priority to US10/450,826 priority patent/US20040101818A1/en
Publication of WO2002050301A2 publication Critical patent/WO2002050301A2/en
Publication of WO2002050301A3 publication Critical patent/WO2002050301A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention identifies genes whose expression pattern is altered when precursor stem cells undergo differentiation into osteoblasts. The genes identified may be used as markers for the differentiation process. The present invention also provides methods to screen agents that are capable of modulating the differentiation process. The present invention also provides methods of identifying therapeutic agents that stimulate bone information by analyzing the expression of one or more of the genes identified.
PCT/US2001/048276 2000-12-18 2001-12-18 Gene expression profiles associated with osteoblast differentiation WO2002050301A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002433436A CA2433436A1 (en) 2000-12-18 2001-12-18 Gene expression profiles associated with osteoblast differentiation
AU2002230820A AU2002230820A1 (en) 2000-12-18 2001-12-18 Gene expression profiles associated with osteoblast differentiation
US10/450,826 US20040101818A1 (en) 2001-12-18 2001-12-18 Gene expression profiles associated with osteoblast differentiation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25588200P 2000-12-18 2000-12-18
US60/255,882 2000-12-18
US28569101P 2001-04-24 2001-04-24
US60/285,691 2001-04-24

Publications (2)

Publication Number Publication Date
WO2002050301A2 WO2002050301A2 (en) 2002-06-27
WO2002050301A3 true WO2002050301A3 (en) 2003-06-05

Family

ID=26945029

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/048276 WO2002050301A2 (en) 2000-12-18 2001-12-18 Gene expression profiles associated with osteoblast differentiation

Country Status (3)

Country Link
AU (1) AU2002230820A1 (en)
CA (1) CA2433436A1 (en)
WO (1) WO2002050301A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7118912B2 (en) 2002-08-26 2006-10-10 Case Western Reserve University Methods and compositions for categorizing patients
US7081516B2 (en) 2002-08-26 2006-07-25 Case Western Reserve University Methods for categorizing patients
US20060035237A1 (en) 2002-08-26 2006-02-16 Markowitz Sanford D Methods and compositions for categorizing patients
EP2280030A3 (en) 2001-04-10 2011-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
GB0215224D0 (en) * 2002-07-01 2002-08-14 Inpharmatica Ltd Protein
US20050208595A1 (en) * 2004-03-19 2005-09-22 Brown Arthur M High throughput assay systems and methods for identifying agents that alter expression of cellular proteins
AU2008296927C1 (en) 2007-09-06 2015-08-13 Case Western Reserve University Methods for diagnosing and treating cancers
EP2569433A4 (en) * 2010-05-10 2013-10-23 Univ Manitoba Modulation of scleraxis using a dominant negative scleraxis mutant with a basic dna-binding domain deletion

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JANTZEN H.M. ET AL.: "Nucleolar transcription factor hUBF contains a DNA-binding motif with homology to HMG proteins", NATURE, vol. 344, April 1990 (1990-04-01), pages 830 - 836, XP002959629 *

Also Published As

Publication number Publication date
AU2002230820A1 (en) 2002-07-01
CA2433436A1 (en) 2002-06-27
WO2002050301A2 (en) 2002-06-27

Similar Documents

Publication Publication Date Title
WO2003053340A3 (en) Antisense modulation of connective tissue growth factor expression
IL206009A (en) Screening methods for the identification and selection of inhibitors of formation of pyroglutamic acid
WO2004005460A3 (en) Antisense modulation of hmg-coa reductase expression
WO2004044181A3 (en) Antisense modulation of apolipoprotein b expression
MX2007008065A (en) Compositions and methods for modulating gene expression using self-protected oligonucleotides.
WO2003097662A8 (en) Antisense modulation of apolipoprotein b expression
WO2004055162A3 (en) Modulation of endothelial lipase expression
WO2002050301A3 (en) Gene expression profiles associated with osteoblast differentiation
WO2003023004A3 (en) Antisense modulation of fibroblast growth factor receptor 3 expression
ATE421574T1 (en) CELL CULTURE METHOD FOR GENERATING PROSTATE-LIKE ACINI
WO2004009024A3 (en) Modulation of protein kinase c-iota expression
WO2003105755A3 (en) Antisense modulation of vegf-c expression
WO2003053341A3 (en) Antisense modulation of ship-1 expression
WO2002062954A3 (en) Antisense modulation of casein kinase 2-beta expression
WO2002062818A3 (en) Antisense modulation of casein kinase 2-alpha expression
UA93538C2 (en) Aurora kinase modulators and method of use
MXPA02001204A (en) Calcilytic compounds.
WO2003099224A3 (en) Antisense moodulation of kinesin-like 1 expression
DE60321445D1 (en) USE OF 4- (2-FLUOROPHENYL) -6-METHYL-2- (1-PIPERAZINYL) THIENO (2,3-D) PYRIMIDINE FOR THE TREATMENT OF HARNINE CONTINENCE
WO2003070878A3 (en) Antisense modulation of hematopoietic cell protein tyrosine kinase expression
EP1923401A3 (en) Gene expression associated with osteoblast differentiation
WO2004045527A3 (en) Modulation of nima-related kinase 6 expression
PL1716128T3 (en) Substituted 4,5,6,7-tetrahydro-benzothiazol-2-ylamine compounds
WO2003027229A3 (en) Antisense modulation of rip2 expression
WO2004016749A3 (en) Antisense modulation of acyl-coa synthetase 1 expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2433436

Country of ref document: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10450826

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP